Neurotech International Financials
NTI Stock | 0.05 0 6.00% |
Neurotech | Select Account or Indicator |
Please note, the imprecision that can be found in Neurotech International's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Neurotech International. Check Neurotech International's Beneish M Score to see the likelihood of Neurotech International's management manipulating its earnings.
Neurotech International Stock Summary
Neurotech International competes with Centaurus Metals, Falcon Metals, Perseus Mining, Hansen Technologies, and Ainsworth Game. Neurotech International is entity of Australia. It is traded as Stock on AU exchange.Foreign Associate | USA |
Specialization | Health Care, Health Care Equipment & Services |
Instrument | Australia Stock View All |
Exchange | Australian Securities Exchange |
ISIN | AU000000NTI9 |
Business Address | 145 Stirling Highway, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.neurotechinternational.com |
Phone | 61 8 9389 3130 |
You should never invest in Neurotech International without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Neurotech Stock, because this is throwing your money away. Analyzing the key information contained in Neurotech International's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Neurotech International Key Financial Ratios
Neurotech International's financial ratios allow both analysts and investors to convert raw data from Neurotech International's financial statements into concise, actionable information that can be used to evaluate the performance of Neurotech International over time and compare it to other companies across industries.Revenue | 1.96 K | ||||
Gross Profit | 3.17 M | ||||
EBITDA | (8.24 M) | ||||
Net Income | (5.07 M) | ||||
Total Asset | 12.21 M |
Neurotech International Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 80.8K | 5.0M | 2.0M | 5.3M | 12.2M | 4.3M | |
Other Current Liab | 8.4K | 25.4K | 72.9K | 57.8K | 35.9K | 17.3K | |
Net Tangible Assets | (646.3K) | 3.9M | 1.4M | 4.0M | 589.6K | 560.1K | |
Retained Earnings | (17.9M) | (25.3M) | (28.7M) | (36.4M) | (41.6M) | (1.2M) | |
Accounts Payable | 664.5K | 324.0K | 520.1K | 1.3M | 278.8K | 150.2K | |
Cash | 12.4K | 4.8M | 1.9M | 3.0M | 11.6M | 1.8M | |
Net Receivables | 59.3K | 142.9K | 99.5K | 257.6K | 318.1K | 164.8K | |
Inventory | 2.5K | 2.4K | 7.2K | 7.8K | 21.3K | 34.6K | |
Other Current Assets | 9.1K | 35.7K | 18.2K | 16.8K | 269.6K | 51.3K | |
Total Liab | 727.1K | 1.1M | 593.0K | 1.3M | 314.7K | 2.1M | |
Total Current Assets | 80.8K | 5.0M | 2.0M | 5.3M | 12.2M | 2.0M | |
Common Stock | 15.5M | 25.8M | 25.8M | 34.4M | 46.7M | 2.5M | |
Net Debt | (4.8M) | (1.9M) | (3.0M) | (11.6M) | (10.5M) | (9.9M) | |
Net Invested Capital | 3.9M | 1.4M | 4.0M | 11.9M | 13.7M | 14.4M | |
Net Working Capital | 4.7M | 1.4M | 4.0M | 11.9M | 13.7M | 14.4M | |
Capital Stock | 25.8M | 25.8M | 34.4M | 46.7M | 53.7M | 29.9M |
Neurotech International Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Revenue | 77.4K | 206.1K | 38.3K | 6.0K | 2.0K | 226.0K | |
Gross Profit | (546.4K) | (238.7K) | (535.2K) | 4.2K | (5.9K) | 105.6K | |
Operating Income | (1.3M) | (7.4M) | (3.9M) | (9.0M) | (5.6M) | (952.4K) | |
Ebit | (1.3M) | (14.9M) | (3.4M) | (9.0M) | (8.2M) | (952.4K) | |
Cost Of Revenue | 623.8K | 444.9K | 573.5K | 1.7K | 7.8K | 108.9K | |
Income Before Tax | (1.7M) | (7.4M) | (3.9M) | (9.0M) | (8.2M) | (881.4K) | |
Net Income | (1.7M) | (7.4M) | (3.4M) | (7.8M) | (5.1M) | (881.4K) | |
Income Tax Expense | (2.0K) | (2.0) | (7.4M) | (569.3K) | (1.2M) | (3.2M) | |
Interest Income | 135.0 | 486.0 | 59.6K | 158.2K | 181.9K | 191.0K | |
Ebitda | (7.4M) | (3.4M) | (9.0M) | (8.2M) | (7.4M) | (7.8M) | |
Net Interest Income | (1.6K) | (883.0) | 59.6K | 158.2K | 181.9K | 191.0K |
Neurotech International Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | 71.0K | (428.9K) | (7.2K) | (579.0) | 7.8K | (11.9K) | |
Change In Cash | (462.3K) | 4.8M | (2.9M) | 1.1M | 6.6M | 1.1M | |
Depreciation | 81.1K | 1.7K | 588.0 | 1.7K | 583.0 | 39.3K | |
Net Income | (1.7M) | (7.4M) | (3.4M) | (7.8M) | (5.1M) | (881.4K) | |
End Period Cash Flow | 12.4K | 4.8M | 1.9M | 3.0M | 11.6M | 3.2M | |
Change To Netincome | 404.3K | 4.8M | 84.0K | 876.6K | 893.1K | 1.3M | |
Free Cash Flow | (2.3M) | (3.0M) | (6.3M) | (4.6M) | (4.1M) | (4.3M) | |
Other Non Cash Items | 240.0K | (195.9K) | 284.9K | 2.2M | 2.0M | 2.1M |
Neurotech Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neurotech International's current stock value. Our valuation model uses many indicators to compare Neurotech International value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neurotech International competition to find correlations between indicators driving Neurotech International's intrinsic value. More Info.Neurotech International is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurotech International's earnings, one of the primary drivers of an investment's value.Neurotech International Systematic Risk
Neurotech International's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Neurotech International volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Neurotech International correlated with the market. If Beta is less than 0 Neurotech International generally moves in the opposite direction as compared to the market. If Neurotech International Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Neurotech International is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Neurotech International is generally in the same direction as the market. If Beta > 1 Neurotech International moves generally in the same direction as, but more than the movement of the benchmark.
Neurotech International Total Assets Over Time
Neurotech International Thematic Clasifications
Neurotech International is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
IT | View |
Neurotech International January 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neurotech International help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neurotech International. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neurotech International based on widely used predictive technical indicators. In general, we focus on analyzing Neurotech Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neurotech International's daily price indicators and compare them against related drivers.
Downside Deviation | 4.49 | |||
Information Ratio | 0.0078 | |||
Maximum Drawdown | 21.71 | |||
Value At Risk | (5.56) | |||
Potential Upside | 5.56 |
Additional Tools for Neurotech Stock Analysis
When running Neurotech International's price analysis, check to measure Neurotech International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurotech International is operating at the current time. Most of Neurotech International's value examination focuses on studying past and present price action to predict the probability of Neurotech International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurotech International's price. Additionally, you may evaluate how the addition of Neurotech International to your portfolios can decrease your overall portfolio volatility.